A
ALNY icon

Astrantus’s Alnylam Pharmaceuticals ALNY Stock Holding History

Astrantus’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$310K Sell
1,900
-1,520
-44% -$232K 0.52% 111
2021
Q4 		$580K Buy
+3,420
New +$636K 0.43% 97

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Astrantus's ALNY Position: Q1 2022 in Review

Astrantus reduced its Alnylam Pharmaceuticals (ALNY) stake by 44% in Q1 2022, selling an estimated $232K and leaving 1,900 shares worth $310K. The position accounts for 0.52% of the portfolio, ranked #111.

Astrantus first reported a position in ALNY in Q4 2021 and has held it in 2 quarters since. The position peaked at $580K in Q4 2021. 444 funds tracked by Wall St. Rank hold ALNY as of Q1 2022.

  • Astrantus held 1,900 shares of Alnylam Pharmaceuticals worth $310K as of Q1 2022.
  • Astrantus sold 1,520 Alnylam Pharmaceuticals shares in Q1 2022, an estimated $232K.
  • Alnylam Pharmaceuticals made up 0.52% of Astrantus's portfolio in Q1 2022, its #111 holding.
  • Astrantus first reported a position in Alnylam Pharmaceuticals in Q4 2021 and has held it in 2 quarters since.
  • Astrantus's Alnylam Pharmaceuticals position peaked at $580K in Q4 2021.
  • 444 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2022.

Based on Astrantus's 13F filing for Q1 2022, filed 11 May 2022.